ARTICLE | Company News

AnGes cardiovascular news

March 5, 2012 8:00 AM UTC

AnGes will pay ¥75 million ($930,000) in remuneration for a patent owned by an outside director of the company's board which covers the use of a human hepatocyte growth factor ( HGF/SF) plasmid for peripheral arterial disease (PAD). The remuneration is a result of discussions between the board member and AnGes, and not a lawsuit. Details were not disclosed. ...